Systems Immunology Department, Weisman Institute of Science, Rehovot, Israel.
School of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France.
Acta Physiol (Oxf). 2023 Jul;238(3):e14001. doi: 10.1111/apha.14001. Epub 2023 Jun 1.
The microbial community of the gut, collectively termed the gut microbiota, modulates both host metabolism and disease development in a variety of clinical contexts. The microbiota can have detrimental effects and be involved in disease development and progression, but it can also offer benefits to the host. This has led in the last years to the development of different therapeutic strategies targeting the microbiota. In this review, we will focus on one of these strategies that involve the use of engineered bacteria to modulate gut microbiota in the treatment of metabolic disorders. We will discuss the recent developments and challenges in the use of these bacterial strains with an emphasis on their use for the treatment of metabolic diseases.
肠道中的微生物群落,统称为肠道微生物群,在各种临床情况下调节宿主代谢和疾病发展。微生物群可能产生有害影响并参与疾病的发展和进展,但也可能对宿主有益。这导致了近年来针对微生物群的不同治疗策略的发展。在这篇综述中,我们将重点介绍其中一种策略,即使用工程细菌来调节肠道微生物群,以治疗代谢紊乱。我们将讨论这些细菌菌株的最新发展和挑战,重点讨论它们在治疗代谢疾病中的应用。